Search Results (18)

Background and Objectives: The treatment landscape for Rheumatoid Arthritis (RA) has evolved significantly with the introduction of Janus kinase inhibitors (JAKi), such as Tofacitinib (TOFA), which offer a new therapeutic option for patients who have failed or are intolerant to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Safety concerns, particularly related to cardiovascular and cancer risks, prompted a need for additional investigation in real-world clinical settings. This study aimed to evaluate the long-term effectiveness and predictors of response to TOFA in two subpopulations of RA patients, categorized by differing cardiovascular risk profiles. Materials and Methods: This was a retrospective, multicenter observational study conducted as part of the BIRRA project, involving 23 Italian rheumatological referral centers. A total of 213 patients diagnosed with RA and treated with TOFA were included, with data collected on baseline demographics, clinical history, disease activity, and comorbidities. Patients were divided into high-risk and low-risk cardiovascular groups based on age (≥65 years) and the presence of at least one cardiovascular risk factor. Disease activity was assessed at baseline, 6 months, and 12 months using DAS28-ESR and DAS28-CRP. Treatment response was evaluated using intention-to-treat (ITT) and per-protocol (PP) approaches. Predictors of low disease activity (LDA) and remission were assessed through logistic regression, and clustering analyses were used to identify subgroups of patients with different therapeutic responses. Results: The study included 213 patients, with 129 classified as high-risk. For the overall cohort, patients achieving LDA and remission at 6 months were 20% and 12%, respectively, for the ITT analysis, and 29% and 14% for the PP analysis. At 12 months, 26% of patients reached LDA, and 17% achieved remission according to ITT, while for the PP analysis, these rates were 30% and 19%, respectively. No significant differences in remission or LDA rates were observed between the high-risk and low-risk groups. In the high-risk subgroup, 17% of patients reached LDA and 9% achieved remission at 6 months (ITT analysis), while these rates increased to 22% and 13%, respectively, in the PP analysis. At 12 months, 22% achieved LDA and 13% achieved remission in the ITT analysis, while 28% and 17% did so in the PP analysis. The reduction in DAS28-ESR and DAS28-CRP scores was significant (p < 0.001) across all time points for both high-risk and low-risk patients. Logistic regression analyses revealed that none of the baseline characteristics—including age, sex, comorbidities, rheumatoid factor, anti-citrullinated protein antibody (ACPA) positivity, initial disease severity, or treatment history—were significant predictors of remission or LDA at 6 or 12 months. The clustering analysis suggested that older patients, particularly those with worse baseline DAS28 scores, tended to show a less favorable response to treatment, potentially indicating impacts of age-related factors such as immunosenescence on therapeutic outcomes. Conclusions: Tofacitinib demonstrated similar effectiveness in both high- and low-risk cardiovascular subgroups of RA patients, with significant reductions in disease activity observed at both 6 and 12 months. Despite safety concerns related to cardiovascular risk, TOFA remained an effective treatment option across patient subgroups, with no significant differences in remission or LDA rates based on cardiovascular risk profiles. Age appeared to negatively impact treatment response, highlighting the role of immunosenescence in RA management. These findings support the use of TOFA as a personalized therapeutic option for RA, emphasizing the need for careful evaluation of cardiovascular and age-related risks in clinical decision-making. Full article

Increasing delays in the onset of the rainy season and extended dry spells in the Nigerian savannas are complicating the determination of optimal planting dates for rain-fed crops, which increases risks for farmers. This study evaluated the impact of planting dates on soybean [Glycine max (L.) Merr.] performance to identify optimal planting dates for different soybean varieties in two agroecological zones (AEZs) of Nigeria. The study involved six planting dates (15 June, 22 June, 29 June, 6 July, 13 July, and 20 July) and three soybean varieties (TGX-1835-10E, TGX-1951-3F, TGX-1904-6F). Results showed significant differences in growth and yield parameters based on location, variety, and planting date. In the Sudan savanna (SS), AEZ at BUK-Kano, optimal yields (>1500 kg ha⁻¹) were achieved when planting TGX-1835-10E and TGX-1951-3F from 15 to 29 June and TGX-1904-6F on 15 June. Planting beyond 29 June reduces yields by 12–55% for TGX-1835-10E and 27–63% for TGX-1951-3F. For TGX-1904-6F, planting after 15 June reduces yields by 27–90%. In the Northern Guinea savanna (NGS) AEZ at Zaria, optimal yields (>1500 kg ha⁻¹) were obtained when planting TGX-1835-10E and TGX-1951-3F from 15 June to 6 July, and TGX-1904-6F between 15 to 29 June. Delaying planting beyond these dates significantly reduced yields by 18–31% for TGX-1835-10E and 12–20% for TGX-1951-3F and 10–41% for TGX-1904-6F. Full article

Background/Objectives: The Janus kinase inhibitors (JAKi) tofacitinib (TOFA), baricitinib (BARI), upadacitinib (UPA), and filgotinib (FILGO) are effective drugs for the treatment of rheumatoid arthritis. However, the US Food and Drug Administration (FDA) raised concerns about the safety of TOFA after its approval. This prompted the European Medicines Agency (EMA) to issue two safety warnings for limiting TOFA use, then extended a third warning to all JAKi in patients at high risk of developing serious adverse effects (SAE). These include thrombosis, major adverse cardiac events (MACE), and cancer. The purpose of this work was to analyze how the first two safety warnings from the EMA affected the prescribing of JAKi by rheumatologists in Italy. Methods: All patients with rheumatoid arthritis who had been prescribed JAKi for the first time in a 36-month period from 1 July 2019, to 30 June 2022 were considered. Data were obtained from the medical records of 29 Italian tertiary referral rheumatology centers. Patients were divided into three groups of 4 months each, depending on whether the JAKi prescription had occurred before the EMA’s first safety alert (1 July–31 October 2019, Group 1), between the first and second alerts (1 November 2019–29 February 2020, Group 2), or between the second and third alerts (1 March 2021–30 June 2021, Group 3). The percentages and absolute changes in the patients prescribed the individual JAKi were analyzed. Differences among the three groups of patients regarding demographic and clinical characteristics were also assessed. Results: A total of 864 patients were prescribed a JAKi during the entire period considered. Of these, 343 were identified in Group 1, 233 in Group 2, and 288 in Group 3. An absolute reduction of 32% was observed in the number of patients prescribed a JAKi between Group 1 and Group 2 and 16% between Group 1 and Group 3. In contrast, there was a 19% increase in the prescription of a JAKi in patients between Group 2 and Group 3. In the first group, BARI was the most prescribed drug (227 prescriptions, 66.2% of the total), followed by TOFA (115, 33.5%) and UPA (1, 0.3%). In the second group, the most prescribed JAKi was BARI (147, 63.1%), followed by TOFA (65, 27.9%) and UPA (33, 11.5%). In the third group, BARI was still the most prescribed JAKi (104 prescriptions, 36.1%), followed by UPA (89, 30.9%), FILGO (89, 21.5%), and TOFA (33, 11.5%). The number of patients prescribed TOFA decreased significantly between Group 1 and Group 2 and between Group 2 and Group 3 (p ˂ 0.01). The number of patients who were prescribed BARI decreased significantly between Group 1 and Group 2 and between Group 2 and Group 3 (p ˂ 0.01). In contrast, the number of patients prescribed UPA increased between Group 2 and Group 3 (p ˂ 0.01). Conclusions: These data suggest that the warnings issued for TOFA were followed by a reduction in total JAKi prescriptions. However, the more selective JAKi (UPA and FILGO) were perceived by prescribers as favorable in terms of the risk/benefit ratio, and their use gradually increased at the expense of the other molecules. Full article

Sarcopenia is a frequent comorbidity of rheumatoid arthritis (RA). Clinical trials have shown that JAK inhibitors (JAKi) produce an asymptomatic increase in serum creatine kinase (CK) in RA, suggesting an impact on muscle. We evaluated the effect of JAKi in muscle remodeling in an experimental RA model. Antigen-induced arthritis (experimental RA, e-RA) was performed in 14 rabbits. Seven rabbits received tofacitinib (TOFA, orally 10 mg/kg/day). Animals were euthanized one day after the last ovalbumin injection, and muscles were prepared for histology, RT-PCR, and WB. C-reactive protein (CRP) and Myostatin (MSTN) serum concentration were determined by ELISA. Creatine and creatine kinase (CK) were analyzed. An increase in body weight as well as tibialis anterior cross-sectional area and diameter was observed in e-RA+TOFA vs. e-RA. e-RA decreased type II fibers and increased the myonuclei number, with all reverted by TOFA. TOFA did not modify CRP levels, neither did MSTN. TOFA significantly reduced IL-6, atrogin-1, and MuRF-1 compared with e-RA. e-RA+TOFA showed higher CK and lower creatine levels compared with e-RA. No differences in PAX-7 were found, while TOFA prevented the increase in MyoD1 in e-RA. Our model reflects the features of rheumatoid sarcopenia in RA. JAKi increased muscle mass through attenuating IL-6/JAK/STAT activation, decreasing atrogenes, and restoring muscle differentiation markers. These data together with an increase in CK support the role of CK as a valuable marker of muscle gain following JAKi treatment. Full article

Background: Tofacitinib (TOFA) was the first Janus kinase inhibitor (JAKi) to be approved for the treatment of rheumatoid arthritis (RA). However, data on the retention rate of TOFA therapy are still far from definitive. Objective: The goal of this study is to add new real-world data on the TOFA retention rate in a cohort of RA patients followed for a long period of time. Methods: A multicenter retrospective study of RA subjects treated with TOFA as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) was conducted in 23 Italian tertiary rheumatology centers. The study considered a treatment period of up to 48 months for all included patients. The TOFA retention rate was assessed with the Kaplan–Meier method. Hazard ratios (HRs) for TOFA discontinuation were obtained using Cox regression analysis. Results: We enrolled a total of 213 patients. Data analysis revealed that the TOFA retention rate was 86.5% (95% CI: 81.8–91.5%) at month 12, 78.8% (95% CI: 78.8–85.2%) at month 24, 63.8% (95% CI: 55.1–73.8%) at month 36, and 59.9% (95% CI: 55.1–73.8%) at month 48 after starting treatment. None of the factors analyzed, including the number of previous treatments received, disease activity or duration, presence of rheumatoid factor and/or anti-citrullinated protein antibody, and presence of comorbidities, were predictive of the TOFA retention rate. Safety data were comparable to those reported in the registration studies. Conclusions: TOFA demonstrated a long retention rate in RA in a real-world setting. This result, together with the safety data obtained, underscores that TOFA is a viable alternative for patients who have failed treatment with csDMARD and/or biologic DMARDs (bDMARDs). Further large, long-term observational studies are urgently needed to confirm these results. Full article

Cowpea is a multifaceted crop; however, considerable challenges affect the production of this crop despite its comparatively better adaptation to harsh environments. Most smallholder farmers in West Africa cultivate this crop in intercropping systems where its low plant population does not allow the full expression of the cultivars’ yield potential. This is because most varieties currently grown in intercrop have been developed in and for monocropping, although some breeding programs recently have focused on intercrop systems. This study, therefore, aimed to evaluate the performance of some newly developed cowpea breeding lines for adaptation to intercropping systems. Firstly, an on-station field experiment was conducted in 2018. The selected promising lines and a standard check were evaluated in three locations in an intercropping system and on-farm trials. Significant differences were observed among the cowpea genotypes for all the traits measured. Two improved lines, UAM14-122-17-7 and UAM14-123-18-3, had superior grain and fodder yields under sole and intercropping systems and in different agroecological systems, revealing their adaptability. Based on our findings, UAM14-122-17-7 and UAM14-123-18-3 are recommended for a cereal-cowpea mixture because they are adapted to intercropping and produce high-grain yield under intercrop and sole-cropping systems. Full article

In the context of climate change, the sowing date and cultivar choice can influence the productivity of sorghum, especially where production is constrained by low soil fertility and early terminal drought across the challenging agro-ecologies of north-eastern Nigeria. Planting within an optimal sowing window to fit the cultivar’s maturity length is critical for maximizing/increasing the crop yield following the appropriate climate-smart management practices. In this study, the APSIM crop model was calibrated and validated to simulate the growth and yield of sorghum cultivars with differing maturing periods sown within varying planting time windows under improved agricultural practices. The model was run to simulate long-term crop performance from 1985 to 2010 to determine the optimal planting windows (PWs) and most suitable cultivars across different agro-ecological zones (AEZs). The performance of the model, validated with the observed farm-level grain yield, was satisfactory across all planting dates and cropping systems. The model predicted a lower mean bias error (MBE), either positive or negative, under the sole cropping system in the July sowing month compared to in the June and August sowing months. The seasonal climate simulations across sites and AEZs suggested increased yields when using adapted sorghum cultivars based on the average grain yield threshold of ≥1500 kgha⁻¹ against the national average of 1160 kgha⁻¹. In the Sudan Savanna (SS), the predicted optimum PWs ranged from 25 May to 30 June for CSR01 and Samsorg-44, while the PWs could be extended to 10 July for ICSV400 and Improved Deko. In the Northern Guinea Savanna (NGS) and Southern Guinea Savanna (SGS), the optimal PWs ranged from 25 May to 10 July for all cultivars except for SK5912, for which predicted optimal PWs ranged from 25 May to 30 June. In the NGS zone, all cultivars were found to be suitable for cultivation with exception of SK5912. Meanwhile, in the SGS zone, the simulated yield below the threshold (1500 kgha⁻¹) could be explained by the sandy soil and the very low soil fertility observed there. It was concluded that farm decisions to plant within the predicted optimal PWs alongside the use of adapted sorghum cultivars would serve as key adaptation strategies for increasing the sorghum productivity in the three AEZs. Full article

Background: Baricitinib (BARI) or Tofacitinib (TOFA) were the first Janus Kinase Inhibitors (JAKi) to be marketed in rheumatoid arthritis (RA). Concerns regarding venous thromboembolism (VTE) risk have emerged during the past years. The aim of the study was to compare the baseline characteristics of patients initiating BARI or TOFA in RA before versus after European Medicine Agency (EMA)’s VTE warnings and to compare real-world persistence with these two drugs. Methods: In this multicentric cohort study, RA patients initiating BARI or TOFA were included from October 2017, date of BARI marketing authorization in France, to September 2020. Baseline characteristics regarding VTE risk were compared (before vs. after May 2019) by using pre-specified statistical tests. Comparison of persistence was assessed by using propensity-score methods. Results: 232 patients were included; 155 with BARI and 77 with TOFA. Baseline characteristics of patients regarding VTE risk factors were not statistically different when Janus Kinase inhibitor (JAKi) was initiated before vs. after EMA’s warnings although a trend towards a lower proportion of VTE history was observed. Five VTE events occurred, four with BARI, one with TOFA. Cumulative persistence rate at 2 years was similar between BARI and TOFA: HR 0.96; 95% Cl: 0.52 to 1.74; p = 0.89. Conclusions: Our study did not show a significant change in patients characteristics starting a JAKi after the EMA’s warnings, probably due to a lack of power. Though, the lower proportion of VTE history in patients after May 2019 suggests that rheumatologists have taken into account the potential VTE risk. These results need to be confirmed by further evidence. Full article

We have recently reported on how transplantation of human mesenchymal stem cells (MSCs) into the mouse parenchyma generated immune responses. To facilitate the clinical translation of MSC-based AD therapy, the safety and efficacy of human derived MSCs (hMSCs) must be confirmed in the pre-clinical stage. Thus, it is imperative to investigate measures to reduce immune responses exerted via xenotransplantation. In this study, immunosuppressants were co-administered to mice that had received injections of hMSCs into the parenchyma. Prior to performing experiments using transgenic AD mice (5xFAD), varying immunosuppressant regimens were tested in wild-type (WT) mice and the combination of dexamethasone and tofacitinib (DexaTofa) revealed to be effective in enhancing the persistence of hMSCs. According to transcriptome sequencing and immunohistochemical analyses, administration of DexaTofa reduced immune responses generated via transplantation of hMSCs in the parenchyma of 5xFAD mice. Significant mitigation of amyloid burden, however, was not noted following transplantation of hMSCs alone or hMSCs with DexaTofa. The efficacy of the immunosuppressant regimen should be tested in multiple AD mouse models to promote its successful application and use in AD stem cell therapy. Full article

We investigated the importance of the baseline expression of genes involved in energy generation, as prognostic biomarkers of the treatment response to tofacitinib in patients with rheumatoid arthritis (RA). Peripheral blood samples were obtained from 28 patients with RA who received 3 months of tofacitinib therapy from 26 healthy controls. Clinical response was evaluated based on the disease activity score, the erythrocyte sedimentation rate (DAS28-ESR), and the serum levels of ACPA, RF, CRP, and ESR. Clinical remission was assessed based on DAS28 score <2.6. Protein concentrations were measured using ELISA. Total RNA isolated from whole blood was used for gene expression analysis using quantitative RT-PCR. All patients were diagnosed with Steinbrocker’s radiographic stage II-III at baseline, and most showed erosive arthritis with ACPA and RF positivity. Tofacitinib treatment significantly decreased the disease activity. Upon study completion, seven patients showed remission. Before and after TOFA therapy, a significantly higher expression of succinate dehydrogenase and pyruvate kinase genes was observed in all the examined patients compared to healthy subjects. However, the pre-therapy expression of these genes and corresponding proteins was significantly (p ≤ 0.05) lower in patients who showed remission than in other patients with RA. Moreover, we observed that, during follow-up, patients who developed remission showed an increasing trend in the expression of the examined genes, whereas the others showed some decreases in gene expression, although this was not statistically significant. We concluded that, compared with RA patients maintaining persistent moderate or high disease activity, those with clinical remission following tofacitinib treatment showed a significantly lower baseline expression of genes involved in energy generation. Full article

This study compared the yield of biodiesel produced from tall oil fatty acids (TOFA) via (i) homogeneous catalyst (sulfuric acid) and (ii) a heterogeneous catalyst (Amberlyst^® BD20, together with Ambersep BD 19 (Midcontinental Chemical Co., Olathe, KS, USA)^® using a batch reactor. The effect of operation conditions including temperature, catalyst concentration, methanol: oil ratio and reaction time on esterification yield were investigated. Gas chromatographic data showed that the major fatty acids present in the TOFA are oleic acid (C18:1n9) and linoleic acid (C18:2n6). Homogenous catalysis yielded 96.76% biodiesel compared to 90.24% for heterogeneous catalysis. Optimized conditions for homogenous catalysis were at a catalyst concentration of 0.5 w/w%, 15:1 methanol: oil mass ratio at 55 °C for 60 min. FTIR results also showed that the homogeneous catalyst yielded a more complete reaction toward biodiesel production in a shorter time (60 min) compared to the heterogeneous catalyst (4.7 h). For heterogeneous catalysis, the highest yield and the lowest acid value were achieved after a second recycling because the reactants were not fully in contact with the catalyst during the first recycling. The catalyst did not show a reduction in catalytic activity even after the fourth recycling. However, the acid value was higher than that for ASTM standards for biodiesel. Full article

This paper assessed the application of the Agricultural Production Systems sIMulator (APSIM)–maize module as a decision support tool for optimizing nitrogen application to determine yield and net return of maize production under current agricultural practices in the Nigeria savannas. The model was calibrated for two maize varieties using data from field experiments conducted under optimum conditions in three locations during the 2017 and 2018 cropping seasons. The model was evaluated using an independent dataset from an experiment conducted under different nitrogen (N) levels in two locations within Southern and Northern Guinea savannas. The results show that model accurately predicted days to 50% anthesis and physiological maturity, leaf area index (LAI), grain yield and total dry matter (TDM) of both varieties with low RMSE and RMSEn (%) values within the range of acceptable statistics indices. Based on 31-year seasonal simulation, optimum mean grain yield of 3941 kg ha⁻¹ for Abuja, and 4549 for Kano was simulated at N rate of 120 kg ha^–1 for the early maturing variety 2009EVDT. Meanwhile in Zaria, optimum mean yield of 4173 kg ha^–1 was simulated at N rate of 90 kg ha⁻¹. For the intermediate maturing variety, IWDC2SYNF2 mean optimum yields of 5152, 5462, and 4849 kg ha⁻¹, were simulated at N application of 120 kg ha⁻¹ for all the locations. The probability of exceeding attainable mean grain yield of 3000 and 4000 kg ha⁻¹ for 2009EVDT and IWDC2SYNF2, respectively would be expected in 95% of the years with application of 90 kg N ha⁻¹ across the three sites. Following the profitability scenarios analysis, the realistic net incomes of US$ 536 ha^–1 for Abuja, and US$ 657 ha⁻¹ for Zaria were estimated at N rate of 90 kg ha⁻¹ and at Kano site, realistic net income of US$ 720 ha^–1was estimated at N rate of 120 kg ha⁻¹ for 2009EVDT.For IWDC2SYNF2, realistic net incomes of US$ 870, 974, and 818 ha⁻¹ were estimated at N application of 120 kg ha⁻¹ for Abuja, Zaria, and Kano respectively. The result of this study suggests that 90 kg N ha⁻¹ can be recommended for 2009EVDT and 120 kg N ha^–1 for IWDC2SYNF2 in Abuja and Zaria while in Kano, 120 kg N ha⁻¹ should be applied to both varieties to attain optimum yield and profit. Full article

A screening Life Cycle Assessment (LCA) of tall oil-based bio-polyols suitable for rigid polyurethane (PU) foams has been carried out. The goal was to identify the hot-spots and data gaps. The system under investigation is three different tall oil fatty acids (TOFA)-based bio-polyol synthesis with a cradle-to-gate approach, from the production of raw materials to the synthesis of TOFA based bio-polyols at a pilot-scale reactor. The synthesis steps that give the most significant environmental footprint hot-spots were identified. The results showed the bio-based feedstock was the main environmental hot-spot in the bio-polyol production process. Future research directions have been highlighted. Full article

The Crop Environment Resource Synthesis (CERES)-Maize model in Decision Support System for Agricultural Technology Transfer (DSSAT) was calibrated and evaluated with experimental data for simulation of response of two intermediate-maturing maize varieties to different sowing dates in the Nigerian savannas. The calibration experiments involved 14 consecutive field trials conducted in the rainy and dry seasons in Bayero University Kano (BUK), Dambatta, and Zaria between 2014–2019. Two sets of field experiments were conducted simultaneously for model evaluation in Iburu in the southern Guinea savanna zone and Zaria in the northern Guinea savanna zone during 2015 and 2016 cropping seasons. The experiments for calibration had two maize (SAMMAZ-15 and SAMMAZ-16) varieties planted under optimum conditions with no water and nutrients stresses. The trials for model evaluation were conducted using the same varieties under four different nitrogen (N) rates (0, 60, 120 and 180 kg N ha⁻¹). A 30-year (1985–2014) term simulation was performed to determine effect of varying sowing dates on yields of two maize varieties (SAMMAZ-15 and SAMMAZ-16) in the Sudan savanna (SS), northern Guinea savanna (NGS), and southern Guinea savanna (SGS) zones. The calibration results showed that the cultivar coefficients of the two maize varieties resulted in simulated growth and development parameters that were in good agreement with observed parameters. Model evaluation showed a good agreement between simulated and observed data for phenology and growth of maize. This demonstrated the potential of the CERES-Maize model to simulate growth and yield of maize in the Nigeria savannas. Results of 30-year sensitivity analysis with 9 different sowing windows showed that in SS, sowing the intermediate maize varieties from early to mid-June produced the highest grain yields. In NGS, the optimum sowing windows were found between late June and late July for the both varieties. In SGS, the optimum sowing window is from early June to late July for SAMMAZ-15 and mid-June to late July for SAMMAZ-16. These planting windows gave the highest long-term average yields for each variety. The variety SAMMAZ-15 was found to be best performing across the three agro-ecologies. Maize performance was generally higher in NGS than in SGS. SS in the Sudan savanna recorded the lowest yield compared with other locations. Full article

Use of small doses of imazapyr and pyrithiobac for seed coatings of imazapyr-resistant maize hybrids (IR-Maize) offers an effective means to control Striga hermonthica. Field trials were conducted in Bauchi and Kano States of Nigeria in 2014 and 2015 under heavy Striga infestation to evaluate the potential effectiveness of herbicide coated hybrids maize on Striga control in farmers’ field. Results showed that herbicide coated seeds reduced number of emerged Striga per m² and Striga damage symptoms in farmers’ fields in all the locations. In Kano the number of emerged Striga was 4.9 to 7.9 times less in herbicide treated hybrids in comparison with those of the same hybrids planted without herbicide treatment. The Striga-resistant open pollinated variety (OPV) (TZL COMP1 SYN) had 6.7 to 8.0 times more Striga than the treated hybrids. In Bauchi, the number of emerged Striga on the untreated IR-maize hybrids were over four-times higher on the treated IR-maize hybrids than on the untreated hybrids. The Striga-resistant OPV check had four-times more Striga than the treated IR-maize hybrids and twice more than the untreated IR-maize hybrids across the two years. However, the effects of herbicide seed coating on grain yields were not consistent because of strong seasonal effects. The result revealed that coating of imazapyr-resistant hybrid maize seeds with imazapyr was effective in reducing Striga infestation in farmers’ fields. Although herbicide seed coating did not give consistent yield advantages of the hybrids over the untreated checks, a combination of herbicide seed treatment and genetic resistance to Striga would serve as an effective integrated approach that could significantly reduce the parasite seed bank from the soil and prevent production of new seeds. The IR-hybrids and the OPV checks contained Striga resistance/tolerant genes that protected them against drastic yield loss in the Striga infested fields in both Bauchi and Kano. Full article